|
Q4 FY2026
As of Jun 30, 2026
|
Q3 FY2026
As of Mar 31, 2026
|
Q2 FY2026
As of Dec 31, 2025
|
Q1 FY2026
As of Sep 30, 2025
|
Q4 FY2025
As of Jun 30, 2025
|
Q3 FY2025
As of Mar 31, 2025
|
Q2 FY2025
As of Dec 31, 2024
|
Q1 FY2025
As of Sep 30, 2024
|
Q4 FY2024
As of Jun 30, 2024
|
Q3 FY2024
As of Mar 31, 2024
|
Q2 FY2024
As of Dec 31, 2023
|
Q1 FY2024
As of Sep 30, 2023
|
Q4 FY2023
As of Jun 30, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash and due from banks | |||||||||||||
| Interest-bearing deposits at other banks | |||||||||||||
| Federal funds sold | |||||||||||||
| Total cash and cash equivalents | |||||||||||||
| Securities available-for-sale, at fair value | |||||||||||||
| Securities held-to-maturity, at amortized cost | |||||||||||||
| Equity securities, at fair value | |||||||||||||
| Loans receivable, net of allowance for credit losses of $5,076 and $1,116, respectively | |||||||||||||
| Loans receivable, net of allowance for credit losses of $5,533 and $5,582, respectively | |||||||||||||
| Loans receivable, net of allowance for credit losses of $5,938 and $5,362, respectively | |||||||||||||
| Premises and equipment, net | |||||||||||||
| Right-of-use asset | |||||||||||||
| Restricted equity securities, at cost | |||||||||||||
| Accrued interest receivable | |||||||||||||
| Bank owned life insurance | |||||||||||||
| Net deferred tax asset | |||||||||||||
| Goodwill and intangible assets | |||||||||||||
| Other assets | |||||||||||||
| Total assets | |||||||||||||
| Liabilities | |||||||||||||
| Noninterest-bearing | |||||||||||||
| Interest-bearing | |||||||||||||
| Total deposits | |||||||||||||
| Borrowings | |||||||||||||
| Advance payments by borrowers for taxes and insurance | |||||||||||||
| Accrued interest payable | |||||||||||||
| Lease liability | |||||||||||||
| Other liabilities | |||||||||||||
| Total liabilities | |||||||||||||
| Equity | |||||||||||||
| Preferred stock, $0.01 par value, 5,000,000 shares authorized, none issued | |||||||||||||
| Common stock, $0.01 par value, 50,000,000 authorized; 7,934,356 and 8,875,170 shares issued and outstanding as of June 30, 2026 and June 30, 2025, respectively | |||||||||||||
| Additional paid-in capital | |||||||||||||
| Retained earnings | |||||||||||||
| Unearned compensation ESOP | |||||||||||||
| Accumulated other comprehensive loss | |||||||||||||
| Total stockholders' equity | |||||||||||||
| Total liabilities and stockholders' equity |
Loading...
